Mori Hitoshi, Kashiura Masahiro, Suzuki Ichiro, Ono Fumiko, Yoshimura Yuya, Moriya Takashi
Department of Emergency and Critical Care Medicine, Hachinohe City Hospital, Hachinohe, Japan.
Department of Emergency and Critical Care Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Front Neurol. 2025 Jun 17;16:1568572. doi: 10.3389/fneur.2025.1568572. eCollection 2025.
Acute ischemic stroke (AIS) is a leading cause of morbidity and mortality, with outcomes dependent on timely treatment. Tissue plasminogen activator (tPA) and endovascular therapy (EVT) improve outcomes, but delays reduce their efficacy. This study introduced a protocol featuring early participation of neuroendovascular interventionists and evaluated its association with treatment times and outcomes compared with conventional management.
This single-center retrospective study included patients with AIS transported to emergency room (ER) who received tPA or EVT between January 2010 and December 2022. Under the protocol, the stroke team-including neuroendovascular interventionists, who made the final decision on tPA and EVT-was activated by the emergency physician when stroke was suspected based on pre-hospital information. The stroke team was not activated if neuroendovascular interventionists were engaged in other procedures or if the ER physician suspected a non-stroke diagnosis. Upon arrival, the team commenced care, with neuroendovascular interventionists reviewing imaging and determining treatment strategies. Patients were categorized into protocol and conventional groups based on management under the new protocol or standard care. The primary outcome was a favorable neurological outcome, defined as a modified Rankin Scale (mRS) score of 0-2 at discharge. Secondary outcomes included time metrics for initiation of tPA and/or EVT. Logistic regression analysis estimated the effects of the protocol, adjusting for confounders, including age, sex, baseline National Institutes of Health Stroke Scale score, and pre-hospital factors. Secondary outcomes were assessed using multiple linear regression.
This study analyzed 501 patients, with 313 in the protocol group and 188 in the conventional group. Favorable neurological outcomes at discharge (mRS 0-2) were more frequent in the protocol group (44.4% vs. 31.9%; adjusted odds ratio: 2.92, 95% confidence interval [CI]: 1.83-4.66). The protocol group also showed shorter door-to-imaging time (-8.3 min), door-to-needle time (-55.9 min), door-to-puncture time (-59.8 min), and door-to-recanalization time (-73.7 min).
Early engagement of neuroendovascular specialists in the emergency pathway was associated with faster treatment initiation and a higher likelihood of favorable functional status at discharge in this retrospective cohort. Because residual confounding and temporal changes in stroke care cannot be excluded, prospective validation in other settings is warranted.
急性缺血性卒中(AIS)是发病和死亡的主要原因,其预后取决于及时治疗。组织型纤溶酶原激活剂(tPA)和血管内治疗(EVT)可改善预后,但治疗延迟会降低其疗效。本研究引入了一项让神经血管介入专家早期参与的方案,并评估了该方案与治疗时间及预后的关联,同时与传统管理方式进行了比较。
这项单中心回顾性研究纳入了2010年1月至2022年12月期间被送往急诊室(ER)并接受tPA或EVT治疗的AIS患者。根据该方案,当基于院前信息怀疑为卒中时,急诊医生会激活卒中团队,该团队包括神经血管介入专家,他们对tPA和EVT做出最终决策。如果神经血管介入专家正在进行其他手术,或者急诊医生怀疑诊断不是卒中,则不会激活卒中团队。患者到达后,团队开始护理,神经血管介入专家会查看影像并确定治疗策略。根据新方案或标准护理下的管理方式,将患者分为方案组和传统组。主要结局是良好的神经功能结局,定义为出院时改良Rankin量表(mRS)评分为0 - 2分。次要结局包括启动tPA和/或EVT的时间指标。逻辑回归分析估计了该方案的效果,并对包括年龄、性别、基线美国国立卫生研究院卒中量表评分和院前因素在内的混杂因素进行了调整。次要结局使用多元线性回归进行评估。
本研究分析了501例患者,其中方案组313例,传统组188例。方案组出院时良好的神经功能结局(mRS 0 - 2)更为常见(44.4%对31.9%;调整后的优势比:2.92, 95%置信区间[CI]:1.83 - 4.66)。方案组的门到影像时间(-8.3分钟)、门到针时间(-55.9分钟)、门到穿刺时间(-59.8分钟)和门到再通时间(-73.7分钟)也更短。
在这个回顾性队列中,神经血管专科医生在急诊流程中的早期参与与更快开始治疗以及出院时获得良好功能状态的更高可能性相关。由于不能排除残留混杂因素和卒中护理的时间变化,因此有必要在其他环境中进行前瞻性验证。